--- title: Obesity studied at Profil description: The worldwide prevalence of obesity has doubled over the past three decades, contributing to a marked increase in type 2 diabetes mellitus. --- [![profil-logo-wortbild-with claim-4c-offset_1000px](https://www.profil.com/hs-fs/hubfs/profil-logo-wortbild-with%20claim-4c-offset_1000px.png?width=250&name=profil-logo-wortbild-with%20claim-4c-offset_1000px.png "profil-logo-wortbild-with claim-4c-offset_1000px")](https://www.profil.com?hsLang=en-us) [![Contact](https://no-cache.hubspot.com/cta/default/481167/1f89c7d1-107f-4c8d-aa7b-f85d0dce14da.png)](https://cta-redirect.hubspot.com/cta/redirect/481167/1f89c7d1-107f-4c8d-aa7b-f85d0dce14da) [Patient information](https://www.profil.de) # [![Header_1077x260px_Obesity_Treatment](https://www.profil.com/hs-fs/hubfs/BLUE_MOON/Header/Header_1077x260px_Obesity_Treatment.jpg?width=1077&height=260&name=Header_1077x260px_Obesity_Treatment.jpg) Obesity Learn about Profil's expertise in the area of obesity](https://www.profil.com/expertise/obesity#) ## Obesity The worldwide prevalence of obesity has doubled over the past three decades, contributing to a marked increase in type 2 diabetes mellitus. Obesity contributes to numerous comorbid conditions. Obese patients are at increased risk of developing many medical problems, including insulin resistance, type 2 diabetes mellitus, hypertension, dyslipidemia, cardiovascular disease, stroke, sleep apnoea, gall bladder disease, hyperuricemia, gout, osteoarthritis and even certain cancers. Whereas drugs initially marketed for weight loss in obesity were relatively inefficacious or suffered from problematic safety profiles, the obesity market changed fundamentally with the advent of GLP-1 receptor agonists. These drugs, initially developed for type 2 diabetes, were shown to induce substantial weight loss also in people without diabetes. Recently, weight loss in obese people with established cardiovascular disease was shown to reduce mortality. Whereas the proof-of-concept for a new drug under development can often already be picked up in a first in human trial where healthy volunteers already lose weight, more sophisticated methods are needed for mode of action trials. The following are available at Profil: - [Anthropometric parameters ](https://www.profil.com/services/other-methods?hsLang=en-us) -  Body composition  (radiation-free, [BOD POD®](https://www.profil.com/services/bodpod?hsLang=en-us)) -  Body fat distribution (MRI) -  Liver fat content ([MRI-PDFF](https://www.profil.com/services/other-methods?hsLang=en-us)) -  Resting metabolic rate (indirect calorimetry) - [Nutrient-induced thermogenesis (indirect calorimetry)](https://www.profil.com/services/exercise-energy-expenditure?hsLang=en-us) - [Exercise-induced thermogenesis (spiroergometry)](https://www.profil.com/services/exercise-energy-expenditure?hsLang=en-us) -  Physical fitness (spiroergometry) - [Total energy expenditure (doubly labeled water)](https://www.profil.com/services/exercise-energy-expenditure?hsLang=en-us) -  Functional Neuroimaging (fMRI) -  Gastric emptying  -  Biomarker profiles in biological samples (blood samples; tissue biopsies) - Adipose tissue [biopsy ](https://www.profil.com/services/muscle-biopsy?hsLang=en-us) -  Energy intake (buffet-style approach) -  [Food preference, hunger, appetite, fullness and satiety (VAS questionnaires)](https://www.profil.com/services/other-methods?hsLang=en-us)   ** ** ![pikto2.png](https://www.profil.com/hs-fs/hubfs/BLUE_MOON/piktos/Icon_NewWebinar.png?width=62&height=70&name=Icon_NewWebinar.png) ### Online Seminar On-demand Online Seminar: **"Early phase obesity research & ** **how to measure outcomes ** **of interest****"**   [![Watch now](https://no-cache.hubspot.com/cta/default/481167/52ba76b5-3c5a-417b-b1fb-0ca6fa2448e5.png)](https://cta-redirect.hubspot.com/cta/redirect/481167/52ba76b5-3c5a-417b-b1fb-0ca6fa2448e5) ![Leona_Hexagon_neu](https://www.profil.com/hs-fs/hubfs/Leona_Hexagon_neu.png?width=154&height=175&name=Leona_Hexagon_neu.png) ### Our expert **Prof. Dr. Leona Plum-Mörschel** Chief Executive Officer [![Contact](https://no-cache.hubspot.com/cta/default/481167/7d2be928-2810-4791-b064-71c6e16cb1b8.png)](https://cta-redirect.hubspot.com/cta/redirect/481167/7d2be928-2810-4791-b064-71c6e16cb1b8) ![blank.jpg](https://www.profil.com/hs-fs/hubfs/BLUE_MOON/piktos/Icon_References.png?width=49&height=49&name=Icon_References.png) #### References We have published with the following sponsors: ![Referenzen](https://www.profil.com/hubfs/BLUE_MOON/content-bilder/Referenzen.gif "Referenzen") [View more](https://www.profil.com/knowledge-center/references?hsLang=en-us) ![blank.jpg](https://www.profil.com/hs-fs/hubfs/BLUE_MOON/piktos/Icon_Certificates.png?width=44&height=49&name=Icon_Certificates.png) #### Certificates | ![13485_Zertifikatssiegel_black_A3](https://www.profil.com/hubfs/BLUE_MOON/piktos/ISO_134852016_certificate_blue.png) ISO 13485:2016 ![27001_Zertifikatssiegel](https://www.profil.com/hubfs/BLUE_MOON/piktos/ISO_27001_certificate_.png) ISO 27001 | ![9001:2015_Zertifikatssiegel](https://www.profil.com/hubfs/BLUE_MOON/piktos/ISO_9001-2015_certificate.png) ISO 9001:2015 ![9001:2015_Zertifikatssiegel](https://www.profil.com/hubfs/BLUE_MOON/piktos/BVMA_Logo_Certificate_size.png) BVMA Member | | --- | --- | ![blank.jpg](https://www.profil.com/hs-fs/hubfs/BLUE_MOON/piktos/Icon_Publications.png?width=44&height=49&name=Icon_Publications.png) #### Publications Andersen, G. et al. 2020. Clinical Characteristics of a Non-Alcoholic Fatty Liver Disease Population Across the Fibrosis Spectrum Measured by Magnetic Resonance Elastography: Analysis of Screening Data. Adv Ther. 2020 Dec;37(12):4866-4876. [View all](https://www.profil.com/knowledge-center/publications?hsLang=en-us) Worldwide obesity levels are double what they were thirty years ago. A marked increase in the incidence of type 2 diabetes mellitus has accompanied this increase. The number of people with prediabetes exceeds the number with diagnosed diabetes, so prediabetes research is an essential field. The Profil Institute for Metabolic Research is at the forefront of research into this condition, providing traditional and novel techniques to help our partners discover the best diabetes prevention plans. ###### Profil Institut für Stoffwechselforschung GmbH Hellersbergstraße 9 · 41460 - Neuss, Germany Telefon +49-2131-4018-345 · marketing@profil.com [Imprint](https://www.profil.com/imprint?hsLang=en-us) | [Privacy Policy](https://www.profil.com/privacy?hsLang=en-us)